Incyte | INCY - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Agenus USD 35.32M 2.51M 2025-12
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Alnylam Pharmaceuticals USD 133.44M 1.07M 2026-03
Amgen USD 540M 1000K 2026-03
BioCryst Pharmaceuticals USD 213.06M 2.54M 2025-12
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Eli Lilly USD 943.5M 3.33M 2026-03
Exelixis USD 253.7M 8.78M 2026-03
Gilead Sciences USD 1.24B 1000K 2026-03
Incyte USD 199.95M 1.49M 2026-03
Ionis Pharmaceuticals USD 165.9M 3.93M 2026-03
MacroGenics USD 63.32M 60K 2025-12
Merck USD 2.47B 12.72M 2025-12
Moderna USD 391M 2M 2025-09
Nektar Therapeutics USD 20.38M 20.36M 2025-12
Neurocrine Biosciences USD 100.6M 500K 2026-03
Novartis USD 1.91B 60K 2026-03
Novartis USD 1.91B 10.64M 2025-12
Pfizer USD 5.7B 13M 2026-03
PTC Therapeutics USD 81.47M 1.54M 2025-12
Puma Biotechnology USD 5K 0 2024-06
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Sarepta Therapeutics USD 105.57M 607K 2026-03
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vertex Pharmaceuticals USD 254.2M 200K 2026-03